|
[1]VALLA DC, CAZALSHATEM D.Sinusoidal obstruction syndrome[J].Clin Res Hepatol Gastroenterol, 2016, 40 (4) :378-385.
|
|
[2]WANG X, QI X, GUO X.Tusanqi-related sinusoidal obstruction syndrome in China:A systematic review of the literatures[J].Medicine (Baltimore) , 2015, 94 (23) :e942.
|
|
[3]ZHUGE YZ, WANG Y, ZHANG F, et al.Clinical characteristics and treatment of Pyrrolizidine alkaloid-related hepatic vein occlusive disease[J].Liver Int, 2018, 38 (10) :1867-1874.
|
|
[4]LIN G, WANG JY, LI N, et al.Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J].J Hepatol, 2011, 54 (4) :666-673.
|
|
[5]FU PP, XIA Q, LIN G, et al.Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms[J].Drug Metab Rev, 2004, 36 (1) :1-55.
|
|
[6]SEOW LJ, BEH HK, MAJID AM, et al.Anti-angiogenic activity of Gynura segetum leaf extracts and its fractions[J].J Ethnopharmacol, 2011, 134 (2) :221-227.
|
|
[7]YUANDANI, JANTAN I, HUSAIN K.4, 5, 4'-Trihydroxychalcone, 8, 8'- (ethene-1, 2-diyl) -dinaphtalene-1, 4, 5-triol and rutin from Gynura segetum inhibit phagocytosis, lymphocyte proliferation, cytokine release and nitric oxide production from phagocytic cells[J].BMC Complement Altern Med, 2017, 17 (1) :211.
|
|
[8]Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing) [J].J Clin Hepatol, 2017, 33 (9) :1627-1637. (in Chinese) 中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见 (2017年, 南京) [J].临床肝胆病杂志, 2017, 33 (9) :1627-1637.
|
|
[9]SENZOLO M, GERMANI G, CHOLONGITAS E, et al.Veno occlusive disease:Update on clinical management[J].World J Gastroenterol, 2007, 13 (29) :3918.
|
|
[10]FAN CQ, CRAWFORD JM.Sinusoidal obstruction syndrome (hepatic veno-occlusive disease) [J].J Clin Exp Hepatol, 2014, 4 (4) :332-346.
|
|
[11]DELEVE LD, SHULMAN HM, MCDONALD GB.Toxic injury to hepatic sinusoids:Sinusoidal obstruction syndrome (veno-occlusive disease) [J].Semin Liver Dis, 2002, 22 (1) :27-42.
|
|
[12]CHEN Z, HUO JR.Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations[J].Neth J Med, 2010, 68 (6) :252-260.
|
|
[13]BAYRAKTAR UD, SEREN S, BAYRAKTAR Y.Hepatic venous outflow obstruction:Three similar syndromes[J].World JGastroenterol, 2007, 13 (13) :1912-1927.
|
|
[14]SHAO H, CHEN HZ, ZHU JS, et al.Computed tomography findings of hepatic veno-occlusive disease caused by Sedum aizoon with histopathological correlation[J].Braz J Med Biol Res, 2015, 48 (12) :1145-1150.
|
|
[15]YANG S, WU J, LEI S.CT features of hepatic veno-occlusive disease:A meta-analysis[J].Acad Radiol, 2018, 25 (3) :328-337.
|
|
[16]ZHONG L, ZHANG Y.Clinical analysis of 142 cases of hepatic veno occlusive disease induced by Tu sanqi[J].Med Philosophy, 2012, 33 (10) :38-40. (in Chinese) 钟岚, 张一.土三七所致肝小静脉闭塞病142例治疗的临床分析[J].医学与哲学, 2012, 33 (10) :38-40.
|
|
[17]ZHOU HX, DONG XY, BU P, et al.Clinical study of the central venous catheter drainage of seroperitoneum in patients with hepatic veno-occlusive disease[J].Chin J Gastroenterol Hepatol, 2017, 26 (2) :196-198. (in Chinese) 周海祥, 董小耘, 卜平, 等.中心静脉导管引流腹腔积液治疗肝小静脉闭塞病的临床研究[J].胃肠病学和肝病学杂志, 2017, 26 (2) :196-198.
|
|
[18]PESCADOR R, CAPUZZI L, MANTOVANI M, et al.Defibrotide:properties and clinical use of an old/new drug[J].Vascul Pharmacol, 2013, 59 (1-2) :1-10.
|
DownLoad: